Consumer willingness to pay for a hypothetical Chagas disease vaccine in Brazil: A cross-sectional study and the implications

Thannuse Silva Athie, Gesiane Cavalcante Nascimento, Maria José Labis Da Costa, Juliana De Sales Silva, Edna Afonso Reis, Antony Paul Martin, Brian Godman, Isabella Piassi Dias Godoí*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Aim: Chagas disease is a serious public health problem, endemic in 21 countries in Latin America. A future vaccine can contribute to decreasing the number of cases and its complications. Methods: A cross-sectional study was conducted with residents of the northern region of Brazil, on the willingness to pay for a hypothetical vaccine against Chagas disease (effective protection of 80%). Results: We interviewed 619 individuals and seven were excluded from the analysis and the value of willingness to pay was US$23.77 (100.00 BRL). Conclusion: The Northern region of Brazil is one of the largest markets for this vaccine, due to its epidemiological relevance, so economic studies with this vaccine will be important to assist in the assessment of technologies.

Original languageEnglish
Pages (from-to)659-672
Number of pages14
JournalJournal of Comparative Effectiveness Research
Volume10
Issue number8
DOIs
Publication statusPublished - Jun 2021
Externally publishedYes

Keywords

  • Brazil
  • Chagas disease
  • contingent valuation
  • vaccine
  • willingness to pay

Fingerprint

Dive into the research topics of 'Consumer willingness to pay for a hypothetical Chagas disease vaccine in Brazil: A cross-sectional study and the implications'. Together they form a unique fingerprint.

Cite this